Thalassaemia: Research
(asked on 11th December 2024) - View Source
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into thalassaemia research in 2023-24; and which public bodies provided that funding.
Answered by
Feryal Clark
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |